<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

BIODESIX LUNG REFLEX


genestrat

The GeneStrat® blood-based tumor profiling test detects guideline recommended, actionable mutations in patients with non-small cell lung cancer with results typically available within 72 hours.

Learn more about:

BIODESIX LUNG REFLEX TESTING

VERISTRAT TEST

What is the GeneStrat® test?

  • Delivers guideline-recommended, blood-based mutation results: EGFR | EML4-ALK | ROS-1 | RET | BRAF | KRAS
  • Results within 72 hours can expedite time to treatment initiation and complement tissue-based testing1,2
  • Drives treatment strategy and facilitates monitoring

Download GeneStrat report

 

Testing Platform

  • Measures circulating cell-free DNA and RNA using Droplet Digital™ PCR (ddPCR)
  • Highly sensitive and specific mutation detection
  • GeneStrat is clinically validated3,4

LEARN MORE ABOUT DDPCR

Expediting Time to Treatment with Swift and Actionable Results

expediting time graphic

Accurate, actionable genomic results

Our data

Case Studies

Learn how some of the industry’s leading experts are using Biodesix Lung Reflex® testing in their practice.

Jonathan-Kurman

Jonathan Kurman, MD

Froedtert & the Medical College of Wisconsin

Michael-Pritchett

Michael Pritchett, DO, MPH

Chest Center of the Carolines at FirstHealth of the Carolinas

The genes tested in the GeneStrat® test are covered by Medicare and many private payers.

Not restricted by stage of NSCLC or recurrence. Multiple tests per patient per cancer when medically necessary.

Learn more about Reimbursement

Get in touch

Contact us

Data library

Discover more
  1. Bowling M, et al. J Clin Oncol 36, 2018 (suppl; abstr e18519)
  2. Boyle T, et al. Poster presentation: AMP annual meeting. Salt Lake City, UT; 2017.
  1. Mellert, et al. J Mol Diagn. 2017, 19: 404-416.
  2. Mellert, et al. J Vis Exp. 2018 Apr 5;(134).